HELP · Cybin Inc. Common Stock

This strategic collaboration represents a targeted operational advancement for Helus Pharma’s PARADIGM HLP003 Phase 3 program, addressing a known challenge in clinical trial recruitment—particularly among underserved veteran populations facing high rates of depression, PTSD, and suicide. By partnering with TARA Mind, an organization founded by a Navy SEAL veteran and built around real-world evidence and clinician-guided psychedelic-informed care, Helus gains access to trusted community infrastructure and advocacy channels that may accelerate enrollment and improve trial diversity. The timing underscores regulatory tailwinds: the April 18, 2026 Executive Order explicitly calls for expanded research participation and innovation in veteran mental health, lending policy relevance and potential future funding or administrative support. While the agreement does not disclose financial terms, milestones, exclusivity, or intellectual property provisions, its focus on recruitment and outreach signals near-term execution risk mitigation rather than revenue generation or pipeline expansion. For investors, this is a de-risking step for HLP003—a program with Breakthrough Therapy Designation—but does not alter clinical timelines, regulatory pathways, or commercial assumptions absent further disclosure.